Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing L-Malate, Lithium, and X22 (an imidazopyridine derivative) (LMLMX22) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 24/February/2018, 6.13 am